Bristol-Myers Squibb announces regulatory update for Opdivo (nivolumab)
Bristol-Myers Squibb announced the FDA has issued a Complete Response Letter for its sBLA for Opdivo (nivolumab) as a single agent for treatment of previously untreated patients, specifically those with BRAF V600 mutation positive unresectable or metastatic melanoma. November 27, 2015